Rigel Pharmaceuticals, Inc., announced that it has entered into a definitive agreement to acquire the U.S. rights to GAVRETO from Blueprint Medicines Corporation. GAVRETO...
AbbVie Inc., and Tentarix Biotherapeutics announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology....
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced the clearance, by the U.S. Food and...
New England Biolabs, announced the launch of the NEBNext Enzymatic 5hmC-seq Kit a novel enzyme-based method for the specific detection of 5hmC sites. The gentle,...
AbbVie, announced that it has completed its acquisition of ImmunoGen. With the completion of the acquisition, ImmunoGen is now part of AbbVie.
"Together with ImmunoGen,...
